StoxSudeep Pharma Limited
NSE: SUDEEPPHRM · Chemicals
Ask the data
Instant answers about Sudeep Pharma Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 642.3 |
| EBITDA | 221.9 |
| Operating margin | 34.5% |
| Interest | 7.6 |
| Depreciation | 14.8 |
| Profit before tax | 228.1 |
| Tax | 53.8 |
| Net profit | 172.9 |
| EPS ₹ | 15.50 |
| Operating cash flow | 69.5 |
| Capex | 118.2 |
| Dividend paid | 0.0 |
| Total assets | 1,174.9 |
| Equity | 883.3 |
Quarterly performance
last 5 quarters · ₹ crore| SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|
| Revenue | 162.7 | 172.3 | 182.3 | 158.3 | 196.7 |
| Operating profit | 55.5 | 60.0 | 62.6 | 54.9 | 73.2 |
| Operating margin | 34.1% | 34.8% | 34.3% | 34.7% | 37.2% |
| Other income | 10.2 | 6.8 | 6.4 | 5.5 | 6.0 |
| Interest | 2.3 | 1.2 | 2.4 | 2.1 | 2.8 |
| Depreciation | 3.8 | 3.9 | 3.9 | 4.0 | 5.4 |
| Profit before tax | 59.5 | 61.8 | 62.7 | 54.3 | 71.0 |
| Tax | 12.8 | 14.1 | 14.2 | 13.7 | 19.2 |
| Net profit | 45.8 | -2.0 | 48.9 | 40.5 | 51.8 |
| EPS ₹ | 4.20 | 4.29 | 4.38 | 3.59 | 4.59 |
| Revenue YoY | — | — | — | — | 20.9% |
| Profit YoY | — | — | — | — | 13.2% |
Returns & margins
trailing-twelve-month, per quarter| JUN '26 | SEP '26 | |
|---|---|---|
| ROE | 15.1% | 14.5% |
| ROCE | 23.9% | 22.6% |
| Net margin | 19.7% | 19.6% |
| EBITDA margin | 34.5% | 35.3% |
| Debt / equity | 0.17 | 0.20 |
| Interest coverage | 30.97 | 30.46 |
| Asset turnover | 0.58 | 0.53 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|
| Share capital | 9.7 | 11.3 | 11.3 |
| Other equity / reserves | 714.6 | 872.0 | 946.0 |
| Total equity | 724.3 | 883.3 | 957.3 |
| Borrowings | 140.8 | 148.3 | 187.7 |
| Current liabilities | 204.3 | 202.0 | 248.9 |
| Non-current liabilities | 45.0 | 74.8 | 106.9 |
| Total assets | 988.0 | 1,174.9 | 1,328.6 |
| Property, plant & equipment | 226.4 | 224.0 | 400.6 |
| Capital work-in-progress | 126.3 | 178.4 | 53.8 |
| Investments | 0.1 | 0.0 | 0.0 |
| Inventories | 184.4 | 216.1 | 274.9 |
| Receivables | 200.7 | 227.5 | 246.1 |
| Cash & equivalents | 52.0 | 26.7 | 53.8 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 69.5 |
| Cash from investing | -327.2 |
| Cash from financing | 247.3 |
| Capex | 118.2 |
| Free cash flow | -48.6 |
| Dividends paid | 0.0 |
Where the assets sit
Sep '26 · ₹ crorePeer comparison
largest in Chemicals · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | 1,68,402 | 18,608.00 | 74.4 | 21.95 | 29.5% |
| Pidilite Industries Ltd. | 1,60,821 | 1,579.00 | 59.9 | 14.34 | 23.9% |
| SRF Ltd. | 72,931 | 2,460.40 | 143.2 | 4.77 | 3.3% |
| Linde India Ltd. | 58,496 | 6,859.00 | 755.3 | 13.33 | 1.8% |
| Coromandel International Ltd. | 53,808 | 1,824.00 | 31.8 | 428.48 | 1349.1% |
| Gujarat Fluorochemicals Ltd. | 51,320 | 4,665.50 | 75.6 | 6.12 | 8.1% |
| Fertilisers and Chemicals Travancore Ltd. | 48,546 | 750.25 | — | 35.30 | -3.1% |
| Navin Fluorine International Ltd. | 46,221 | 9,010.00 | 50.8 | 10.36 | 20.4% |
| UPL Ltd. | 45,199 | 534.90 | 23.9 | 1.30 | 5.4% |
| Himadri Speciality Chemical Ltd. | 28,669 | 568.15 | 33.5 | 5.58 | 16.6% |
| Sudeep Pharma Limited | 13,309 | 1,178.30 | 95.6 | 13.90 | 14.5% |
StoxGud checklist: Neutral setup · 6/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Sudeep Pharma Limited?
Sudeep Pharma Limited (SUDEEPPHRM) closed at ₹1,178.30 on NSE on 06 Nov 2026.
What is the market cap of Sudeep Pharma Limited?
₹13,309 crore at the latest close.
What is the P/E ratio of Sudeep Pharma Limited?
95.6, on trailing-twelve-month earnings from its filings.
How fast is Sudeep Pharma Limited growing?
Sudeep Pharma Limited: Latest-quarter revenue is up 20.9% year on year, profit up 13.2%.
How profitable is Sudeep Pharma Limited?
On a trailing-twelve-month basis return on equity is 14.5%, return on capital employed 22.6%, operating margin 35.3%, net margin 19.6%.
How much debt does Sudeep Pharma Limited have?
Sudeep Pharma Limited is lightly geared: debt to equity is 0.20 with borrowings of ₹188 cr against cash of ₹54 cr (balance sheet of 2026-09-30). Operating profit covers interest 30.5 times.
Financials parsed from Sudeep Pharma Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '25, annual from FY26, balance sheet from Sep '25. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.